GRAIL, LLC, a pioneering healthcare company dedicated to early cancer detection for potential curative treatment, has partnered with AstraZeneca to include Japanese patients in studies utilizing GRAIL’s innovative Methylation Platform. This cutting-edge test, focused on blood-based detection, is set to classify the recurrence risk in patients newly diagnosed with Stage I lung adenocarcinoma, marking a significant advancement in non-invasive cancer diagnostics.
The collaboration with AstraZeneca aims to validate the test’s effectiveness in delivering rapid results within a 10-day timeframe without necessitating tumor tissue samples, thereby facilitating its use in global pharmaceutical clinical trials. GRAIL’s breakthrough lies in its tissue-free, blood-only methodology, promising a customizable dimensional approach to support precise oncological treatment plans and clinical trial selections.
In 2022, GRAIL and AstraZeneca embarked on a broad strategic collaboration to develop companion diagnostic assays aligned with AstraZeneca’s therapeutic innovations. Following this, in December 2023, GRAIL successfully announced the analytical and clinical validation of a novel prognostic test for Stage I lung adenocarcinoma.
Headquartered in Menlo Park, CA, with additional facilities in Washington, D.C., North Carolina, and the UK, GRAIL’s mission is to mitigate the global cancer burden through early detection technologies. GRAIL is at the forefront of designing a multi-cancer early-detection blood test using advanced next-generation sequencing, comprehensive clinical studies, and sophisticated data science. Despite its achievements, it’s important to note that GRAIL’s productions are yet to receive clearance or approval from the U.S. FDA. GRAIL operates as a subsidiary of Illumina, Inc., under separate management as per the European Commission’s Interim Measures Order.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
